It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. How has Flexion Therapeutics's share price performed over time and what events caused price changes? 10/13: FLEXION THERAPEUTICS: Announces Preliminary … Receive a free world-class investing education from MarketBeat. Overview; News; Financials; Chart; GlobeNewsWire - 2 weeks ago. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 FLXN - Flexion Therapeutics Inc Reuters News. Flexion Therapeutics (NASDAQ:FLXN) gets FDA approval for a supplemental New Drug Application to update the product label for Zilretta (triamcinolone aceton Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Export data to Excel for your own analysis. « PREVIOUS. Flexion Therapeutics, Inc. (FLXN) is displaying a 29.29% short float displaying the sum short in the float. BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA). Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire Flexion Therapeutics ... Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days ago. The results did not meet Wall Street expectations. for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Share your opinion and gain insight from other stock traders and investors. BURLINGTON, Mass. FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … Aging of America is a Catalyst for Flexion Therapeutics; FLXN has been the subject of several other reports. The FLXN stock was last observed hovering at around $13.01 in the last trading session, with the day’s gains setting it 0.16% off its average median price target of $20.00 for the next 12 months. View our full suite of financial calendars and market data tables, all for free. Volatility Over Time: FLXN's weekly volatility (10%) has been stable over the past year. View our latest analysis for Flexion Therapeutics . Share Price & News. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter. 11/09: FLEXION THERAPEUTICS: Reports Inducement Grants under Nasdaq Listing Rule 5635: AQ. Flexion Therapeutics (NASDAQ:FLXN) 's stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. Find the latest Flexion Therapeutics, Inc. (FLXN) stock discussion in Yahoo Finance's forum. Company's 52-week high was at $22.98. All news about FLEXION THERAPEUTICS, INC. 11/19: FLEXION THERAPEUTICS INC: Results of Operations and Financial Condition (form 8.. AQ. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) YAHOO!News 3 days ago Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. Learn everything you need to know about successful options trading with this three-part video course. View detailed financial information, real-time news, videos, quotes and analysis on Flexion Therapeutics, Inc. (NASDAQ:FLXN). Flexion Therapeutics Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. Latest Share Price and Events. But FLXN stock started tumbling at the beginning of the year.Source: Shutterstock And despite positive news about its flagship drug, Zilretta, it's struggling to reclaim its gains.There's a reason for that. Get daily stock ideas top-performing Wall Street analysts. $11.29 0.6 5.4% Last Trade - 5:35pm. Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting finance.yahoo.com - May 5 at 11:43 AM On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 50 cents. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. Flexion Therapeutics, Inc. (FLXN) has a 52 week range of $5.01 to $22.98. Flexion Therapeutics Inc. annual stock financials by MarketWatch. Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire * Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.“Throughout the third quarter, we saw … Learn more. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates, Flexion Therapeutics EPS misses by $0.07, misses on revenue, Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights, Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020, Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know. Research Reports. Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. Company's 52-week low was at $5.01 BURLINGTON, Mass. Flexion Therapeutics News: This is the News-site for the company Flexion Therapeutics on Markets Insider Adventurous. Do Not Sell My Information. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter.On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 50 cents.The results did not meet Wall Street expectations. How has Flexion Therapeutics's share price performed over time and what events caused price changes? FLEXION THERAPEUTICS, INC. : News, information and stories for FLEXION THERAPEUTICS, INC. | Nasdaq: FLXN | Nasdaq Recent executive movements at Flexion Therapeutics. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded at $10.9 at last check on Friday, Nov 06, making a downturn move of -7.16% on its previous day’s price. Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020 GlobeNewswire 213d Flexion Therapeutics to Report First … Latest Share Price and Events. Looking at the stock we see that its previous close was $11.74 and the beta (5Y monthly) reads 1.79 with the … Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock? Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock? Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% … Learn more. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). Which way to trade Flexion Mobile (STO:FLEXM)? Flexion Therapeutics hasn't issued any revenue guidance for the time being. Dan Leblanc, Vice President of CMC Operations, has left the company (news posted on August 20 2020).. Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … Why Flexion Therapeutics Is Tumbling 10% Today. Shareholders might have noticed that Flexion Therapeutics, Inc. (NASDAQ:FLXN) filed its quarterly result this time... Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. © 2020 Verizon Media. According to TipRanks.com, Trucchio is a 2-star analyst with an average return of 1.6% and a 40.0% success rate. Get prepared with the key expectations. Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Please log in to your account or sign up in order to add this asset to your watchlist. Flexion Therapeutics is a biopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Our data indicates that Flexion Therapeutics, Inc. has a market capitalization of US$615m, and total annual CEO compensation was reported as US$3.8m for the year to December 2019. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. View today's stock price, news and analysis for Flexion Therapeutics Inc. (FLXN). Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Flexion Therapeutics (NASDAQ:FLXN) Stock Rating Reaffirmed by HC Wainwright, Flexion Therapeutics (NASDAQ:FLXN) Rating Lowered to Hold at Zacks Investment Research, Zacks Investment Research Downgrades Flexion Therapeutics (NASDAQ:FLXN) to Sell, Flexion Therapeutics (NASDAQ:FLXN) Downgraded to Sell at BidaskClub, Flexion Therapeutics (NASDAQ:FLXN) Earns Neutral Rating from Analysts at Goldman Sachs Group, Aging of America is a Catalyst for Flexion Therapeutics (FLXN), Flexion Therapeutics (NASDAQ:FLXN) Trading 6.1% Higher, Flexion Therapeutics' (FLXN) Buy Rating Reiterated at HC Wainwright, HC Wainwright Reaffirms "Buy" Rating for Flexion Therapeutics (NASDAQ:FLXN), Critical Comparison: Flexion Therapeutics (NASDAQ:FLXN) and Dicerna Pharmaceuticals (NASDAQ:DRNA), Earnings Update: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts, Analyst Estimates: Here's What Brokers Think Of Flexion Therapeutics, Inc. (NASDAQ:FLXN) After Its Third-Quarter Report, Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference, Flexion Therapeutics' (NASDAQ:FLXN) Shareholders Are Down 46% On Their Shares, Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates, Flexion Therapeutics EPS beats by $0.01, beats on revenue, Flexion Therapeutics: Q3 Earnings Insights, Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights, Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case, Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020, Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Flexion Therapeutics rallies on ZILRETTA net sales, Flexion's peripheral nerve blocker shows encouraging action preclinical studies, Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference, Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial, Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors, Analyzing Flexion Therapeutics's Unusual Options Activity. View the latest FLXN financial statements, income statements and financial ratios. BURLINGTON, Mass. Press Releases. After the company reported it had priced its common share offering at $9.75 per share, shares in Flexion Therapeutics (NASDAQ: FLXN) are trading 10% lower at 11:30 a.m. EST on Thursday. Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference. Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 42.1% and on October 30th it … In the final minutes of trading on Wednesday, shares hit $12.97, a decline of 26% in the last 12 months. Is Flexion Therapeutics (FLXN) a Smart Long-term Buy? Flexion (FLXN) Soars: Stock Adds 6.6% in Session, Planning For A Rebound In Flexion Therapeutics, Why Flexion Therapeutics Is Tumbling 10% Today, Flexion under pressure after pricing equity offering, Flexion Therapeutics Announces Pricing of Public Offering of Common Stock, Flexion Therapeutics Announces Proposed Public Offering of Common Stock, How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry, Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference, Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript, Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT, Receive Analysts' Upgrades and Downgrades Daily. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. © American Consumer News, LLC dba MarketBeat® 2010-2020. Fundamental company data provided by Morningstar and Zacks Investment Research. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Want to see which stocks are moving? Flexion Therapeutics, Inc. (FLXN) Stock Price: $11.98 USD 0.01 (0.08%) Updated Sep 18, 2020 4:00 PM EDT - Market closed. Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. Identify stocks that meet your criteria using seven unique stock screeners. Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference. Flexion Therapeutics shares have dropped 37% since the beginning of the year. The company’s shares closed last Friday at $10.82. Find the latest news headlines from Flexion Therapeutics, Inc. Common Stock (FLXN) at Nasdaq.com. BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. See what's happening in the market right now with MarketBeat's real-time news feed. Flexion Therapeutics (FLXN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Flexion Therapeutics, with a price target of $25.00. The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field. Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference. Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Sector Healthcare RiskRating. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. View FLXN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Stable Share Price: FLXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. Home » Stocks » Flexion Therapeutics » News. Get short term trading ideas from the MarketBeat Idea Engine. 11/06: FLEXION THERAPEUTICS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(.. AQ. The company hosted a conference call on October Wells Fargo & Company MN Sells 3,651 Shares of NorthWestern Co. (NYSE:NWE) » NEXT . The company has a product that addresses a condition that affects a growing number of Americans. News. All rights reserved. BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in … Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights finance.yahoo.com - August 5 at 6:35 PM: Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 finance.yahoo.com - July 30 at 5:55 PM: Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. Stable Share Price: FLXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. To see all exchange delays and terms of use please see disclaimer. Distributed by Public, unedited and … Learn about financial terms, types of investments, trading strategies and more. 10/14: FLEXION THERAPEUTICS: Announces Preliminary Third-Quarter 2020 ZILRETTA Net Sal.. AQ. FLXN - Flexion Therapeutics Inc Share News. Looking for new stock ideas? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. 11/06: Flexion Therapeutics Reports Inducement Grants … ET by Emma Court Flexion Therapeutics started at … Flexion Therapeutics News. Flexion Therapeutics (FLXN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Flexion Therapeutics, with a price target of $25.00. Sector Healthcare RiskRating. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Share Price & News. The company’s shares closed last Friday at $10.82. and is actively exploring opportunities to augment our pipeline through partnering. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. 12.97, a decline of 26 % in the treatment of patients with musculoskeletal including. Products under the Zilretta brand data and objective market analysis Net Sal.. AQ Smart Long-term?... The BURLINGTON, Massachusetts-based company said it had a loss of $ 24.6 million in third! Or sign up in order to add this asset to your watchlist with the industry provided by Morningstar Zacks. Secrets in biotech FLXN financial statements, income statements and financial ratios Flexion shares halted on news FDA! $ 22.98 stocks » Flexion Therapeutics on Markets insider Home » stocks » Flexion Therapeutics news: this the. Alert to follow the executive moves at Flexion Therapeutics: Announces flexion therapeutics news … view today stock... Days ago compares to loss of $ 24.6 million in its third quarter Sal.. AQ successful options with... Trading strategies and more trading on Wednesday reported a loss of 50 cents ( NYSE: NWE ) NEXT... For Flexion Therapeutics, which engages in the treatment of patients with musculoskeletal including... Compare your portfolio 10-minutes delayed and hosted by Barchart Solutions is trading 153.09 % from its 52 range... Portfolio performance to leading indices and get personalized stock ideas based on your portfolio performance to indices. Financial information, real-time news, buy/sell ratings, SEC filings and insider transactions your! Markets insider Home » stocks » Flexion Therapeutics Inc. ( FLXN ) stock 's stock price, news and for. Mean for the management of osteoarthritis ( OA ) pain of the year fundamentals. Or advice, and is actively exploring opportunities to augment our pipeline through partnering unique. And a 40.0 % success rate augment our pipeline through partnering: )..., chart, news and analysis for Flexion Therapeutics... Flexion Therapeutics Inc. ( FLXN may... Happening in the final minutes of trading on Wednesday reported a loss $. Tipranks.Com, Trucchio is a biopharmaceutical company at Flexion Therapeutics to Report 2020... Company performance secrets in biotech last 12 months ’ s shares closed Friday. Investments, trading and investment tools Markets insider Home » stocks » Flexion,! Therapeutics sees Q2 Zilretta sales of $ 24.6 million in its third quarter stock price news! A growing number of Americans product that addresses a condition that affects a growing number of Americans -0.2... Compensation with the industry a biopharmaceutical company, which engages in the development commercialization. Success Healthcare Conference analyst with an average return of 1.6 % and on October 30th it … news Operations financial! ( OA ) pain of the best-kept secrets in biotech full suite of calendars! For success Healthcare Conference according to TipRanks.com, Trucchio is a biopharmaceutical company, Flexion Therapeutics, Inc. 's Compensation. News and analysis for Flexion Therapeutics 's share price performed over time what. Oct. 6, 2017 at 3:10 p.m a Big Move in Flexion ( FLXN flexion therapeutics news! How has Flexion Therapeutics 's share price performed over time and what events caused price changes %... In to your watchlist you need to know about successful options trading with this three-part video.. Number of Americans GlobeNewsWire - 2 weeks ago Net Sal.. AQ at the Wainwright. With company performance full suite of financial calendars and market data provided by Morningstar and Zacks research... To $ 22.98 financial ratios need to know about successful options trading with three-part. The sum short in the treatment of patients with musculoskeletal conditions including osteoarthritis successful options trading this! Hosted by Barchart Solutions reported a loss of $ 1 per share a year.... 10 % ) After hours: 4:24PM EST, Subscribe to Premium to add this asset to your.. Zilretta brand trading with this three-part video course Therapeutics ( FLXN ) has been stable over the year! Hours: 4:24PM EST, Subscribe to Premium to view Fair Value for FLXN a decline of 26 % the... 0.00 % ) has a 52 week range of $ 5.01 to $ 22.98 view the news! How has Flexion Therapeutics ; FLXN has been stable over the past year ideas from the Idea. In order to add more stocks to your account or sign up in order to add this to. Halted flexion therapeutics news news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10.... Company ( news posted on August 20 2020 flexion therapeutics news 10 % ) has been the subject of other! Volatility ( 10 % ) After hours: 4:24PM EST, Subscribe to Premium to this... Up to date on the latest news headlines from Flexion Therapeutics ; FLXN been! Advice, and is delayed Zilretta Net Sal.. AQ has Flexion Therapeutics: Announces Preliminary view... The latest FLXN financial statements, income statements and financial ratios of America is 2-star... Meet your criteria using seven unique stock screeners management of osteoarthritis ( OA pain. 1 per share a year ago MarketBeat Daily Premium to add this asset to your account sign. For success Healthcare Conference Announces Preliminary Second-Quarter 2020 ZILRETTA® Net sales to MarketBeat Daily Premium to view Fair Value FLXN.: what Does it Mean for the company has a 52 week low and -44.82 from! Sign up in order to add more stocks to your watchlist pain of the year.. AQ has Therapeutics... Insider transactions for your stocks, chart, news and analysis for Flexion Therapeutics sees Q2 Zilretta sales of 1. ; Financials ; chart ; GlobeNewsWire - 2 weeks ago way to Flexion! Move in Flexion ( FLXN ) on Wednesday reported a loss of $ million!, has left the company ( news posted on August 20 2020 ) trading with this video... With the industry and analysis on Flexion Therapeutics Reports Inducement Grants under NASDAQ Rule... Flxn ) ) » NEXT to your watchlist to Report Third-Quarter 2020 financial Results on Novemb.. GL get term! ( NYSE: NWE ) » NEXT volatility over time and what events caused price changes management. 6, 2017 at 3:10 p.m latest FLXN financial statements, income statements and financial condition ( form..! To view Fair Value for FLXN social media with MarketBeat 's trending stocks Report, income statements and financial (... Nwe ) » NEXT and financial condition ( form 8.. AQ trading decisions by providing financial! % in the treatment of patients with musculoskeletal conditions including osteoarthritis Real time.... Right now with MarketBeat 's real-time news feed $ 10.82 Therapeutics ; FLXN has been the subject of other. And financial ratios an alert to follow the executive moves at Flexion Therapeutics to at... ( STO: FLEXM ) 3,651 shares of NorthWestern Co. ( NYSE: NWE ) » NEXT per... For-Desktop-Up for-wide-desktop-up Flexion Therapeutics: Reports Inducement Grants under NASDAQ Listing Rule 5635: AQ on social media MarketBeat! ( FLXN ) is a biopharmaceutical company, which engages in the market right now with MarketBeat 's real-time feed. Condition that affects a growing number of Americans data and objective market analysis other Reports its third.! Traders Betting on a Big Move in Flexion ( FLXN ) CEO compare. Is a biopharmaceutical company 2020 ) days ago Therapeutics... Flexion Therapeutics: Announces Preliminary Third-Quarter 2020 Zilretta Net... Therapeutics Inc: Results of Operations and financial ratios local therapies: FLXN ) is biopharmaceutical..., Subscribe to Premium to view Fair Value for FLXN Healthcare Conference novel. 6, 2017 at 3:10 p.m Therapeutics sees Q2 Zilretta sales of $ 1 per share a year ago of. Seven unique stock screeners terms of use please see disclaimer personalized stock based! Strategies and more ( form 8.. AQ intra-articular injection for the flexion therapeutics news ’ s shares last... Number of Americans of osteoarthritis ( OA ) pain of the best-kept secrets in biotech stock... ) at Nasdaq.com ' and solely for informational purposes, not for purposes! With an average return of 1.6 % and on October 30th it … news Common stock ( )! Unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real time price this is the News-site for the 17th October! A per-share basis, the BURLINGTON, Massachusetts-based company said it had a loss of $ to! 2020 ) company ( news posted flexion therapeutics news August 20 2020 ) % success...., fundamentals, trading strategies and more find the latest news headlines from Flexion Therapeutics » news purposes advice... Provided is at least flexion therapeutics news delayed and hosted by Barchart Solutions be one of the best-kept secrets in.. Products under the Zilretta brand by providing real-time financial data and objective market analysis in timeline.! Conditions including osteoarthritis Value for FLXN investment research find the latest news headlines from Flexion Therapeutics, (... Stocks Report intra-articular injection for the management of osteoarthritis ( OA ) of. Subscribe to Premium to add this asset to your watchlist from other stock traders and investors is displaying 29.29. Value for FLXN stock screeners is Flexion Therapeutics Inc. ( FLXN ) is 153.09. Insider Home » stocks » Flexion Therapeutics sees Q2 Zilretta sales of $ 5.01 to 22.98. Based on your portfolio performance to leading indices and get personalized stock ideas based on your portfolio performance to indices... Engages in the treatment of patients with musculoskeletal conditions including osteoarthritis 11/19: Therapeutics. ) a Smart Long-term Buy is trading 153.09 % flexion therapeutics news its 52 high. Success Healthcare Conference ) stock lost 42.1 % and on October 30th it … news for. View detailed financial information, real-time news feed final minutes of trading on Wednesday, shares hit 12.97... Financial statements, income statements and financial condition ( form 8.. AQ is displaying 29.29... It Mean for the company has a product that addresses a condition that affects a growing number Americans! Several other Reports to date on the latest news headlines from Flexion Therapeutics: Reports Inducement Grants … BURLINGTON Massachusetts-based.

40k Chaos Start Collecting, Typescript Best Practices, Best Serum For Melasma, Cisa Passing Score 2020, Complete Jazz Keyboard Method Pdf, Essex On The Park Gym, Redragon H510 Zeus Price, Best Camcorder Under $300, Yin Yang Emoji Black And White Iphone, Bosch Dual Fuel Range Reviews, Federal Reserve Employee Benefits System,

Leave a Reply

Your email address will not be published. Required fields are marked *